Literature DB >> 25115743

Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test.

Monika Ferlitsch1, Georg Heinze, Petra Salzl, Martha Britto-Arias, Elisabeth Waldmann, Karoline Reinhart, Christina Bannert, Elisabeth Fasching, Peter Knoflach, Werner Weiss, Michael Trauner, Arnulf Ferlitsch.   

Abstract

Due to high costs and limited availability of screening colonoscopy, some screening programs require a positive fecal occult blood test (FOBT) before screening colonoscopy is remunerated. As male sex is a strong predictor of adenoma and advanced adenoma, we evaluated whether a positive FOBT or male sex is a stronger risk factor for adenoma and advanced adenoma. FOBT and screening colonoscopy results from 18.665 consecutive patients participating in a "national health check program" between 2009 and 2011 were included in this cohort study. Age-corrected adenoma detection rates (ADR), advanced adenoma detection rates (AADR) and carcinoma detection rates were calculated for men and women according to FOBT result separately. ADR and AADR in FOBT-positive men (34.6 and 11.8 %) and FOBT-negative men (29.1 and 7.6 %) were higher than ADR and AADR in FOBT-positive women (20 and 6.9 %) and in FOBT-negative women (17.6 and 4.4 %), (p = 0.0003). Men with negative FOBT were at higher risk of having an adenoma and advanced adenoma than women with positive FOBT (p < 0.0001). Odds ratios of a positive FOBT for ADR and AADR were 1.3 (1.1-1.5) (p = 0.0047) and 1.6 (1.2-2.1) (p < 0.0001), respectively. Odds ratios of male sex to predict ADR and AADR were significantly higher with 1.9 (1.8-2.1) and 1.8 (1.6-2), respectively (p < 0.001). Male sex is a stronger predictor for colorectal adenoma and advanced adenoma than positive FOBT. These results should be taken into account analyzing FOBT-based screening programs.

Entities:  

Mesh:

Year:  2014        PMID: 25115743     DOI: 10.1007/s12032-014-0151-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

Review 1.  Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy.

Authors:  C Hassan; P J Pickhardt; D H Kim; E Di Giulio; A Zullo; A Laghi; A Repici; F Iafrate; J Osborn; B Annibale
Journal:  Aliment Pharmacol Ther       Date:  2009-10-08       Impact factor: 8.171

2.  Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer.

Authors:  Michael Hoffmeister; Stephanie Schmitz; Elisabeth Karmrodt; Christa Stegmaier; Ulrike Haug; Volker Arndt; Hermann Brenner
Journal:  Clin Gastroenterol Hepatol       Date:  2010-07-27       Impact factor: 11.382

3.  Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.

Authors:  S C Ng; J Y L Ching; V Chan; M C S Wong; B Y Suen; H W Hirai; T Y T Lam; J Y W Lau; S S M Ng; J C Y Wu; F K L Chan; J J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2013-08-20       Impact factor: 8.171

4.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

5.  Long-term mortality after screening for colorectal cancer.

Authors:  Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

6.  Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals.

Authors:  David A Lieberman; Sheila Prindiville; David G Weiss; Walter Willett
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

7.  Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer.

Authors:  R J C Steele; P L McClements; G Libby; R Black; C Morton; J Birrell; N A G Mowat; J A Wilson; M Kenicer; F A Carey; C G Fraser
Journal:  Gut       Date:  2008-11-26       Impact factor: 23.059

8.  Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

Authors:  P Rozen; Z Levi; R Hazazi; A Waked; A Vilkin; E Maoz; S Birkenfeld; Y Niv
Journal:  Aliment Pharmacol Ther       Date:  2008-11-17       Impact factor: 8.171

9.  Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia.

Authors:  U Haug; K M Kuntz; A B Knudsen; S Hundt; H Brenner
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

10.  Risk of advanced colorectal neoplasia according to age and gender.

Authors:  Frank T Kolligs; Alexander Crispin; Axel Munte; Andreas Wagner; Ulrich Mansmann; Burkhard Göke
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

View more
  6 in total

1.  Fecal immunochemical test-based colorectal cancer screening: The gender dilemma.

Authors:  Esmée J Grobbee; Els Wieten; Bettina E Hansen; Esther M Stoop; Thomas R de Wijkerslooth; Iris Lansdorp-Vogelaar; Patrick M Bossuyt; Evelien Dekker; Ernst J Kuipers; Manon Cw Spaander
Journal:  United European Gastroenterol J       Date:  2016-07-14       Impact factor: 4.623

2.  Screening Women Aged 50-59 for CRC Using Fecal Occult Blood Test Produces Outcomes Similar to Men Undergoing Screening Colonoscopy.

Authors:  Harrison M Mooers; Jennifer L Holub; David A Lieberman
Journal:  Dig Dis Sci       Date:  2018-06-13       Impact factor: 3.199

3.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

4.  Prevalence of colorectal neoplasms in young, average risk individuals: A turning tide between East and West.

Authors:  Ari Leshno; Menachem Moshkowitz; Maayan David; Lior Galazan; Alfred I Neugut; Nadir Arber; Erwin Santo
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

5.  Factors Related to Non-participation in the Basque Country Colorectal Cancer Screening Programme.

Authors:  M Solís-Ibinagagoitia; S Unanue-Arza; M Díaz-Seoane; L Martínez-Indart; A Lebeña-Maluf; I Idigoras; I Bilbao; I Portillo
Journal:  Front Public Health       Date:  2020-12-11

6.  A Pilot Study Investigating the Expression Levels of Pluripotency-Associated Genes in Rectal Swab Samples for Colorectal Polyp and Cancer Diagnosis and Prognosis.

Authors:  Ryan Wai-Yan Sin; Dominic Chi-Chung Foo; Deepak Narayanan Iyer; May Sau-Yee Fan; Xue Li; Oswens Siu-Hung Lo; Wai-Lun Law; Lui Ng
Journal:  Stem Cells Int       Date:  2021-07-22       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.